Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533486 | 0.83 | APEX1 (0.47) | MEN1KMT2ASMN1; SMN2RAB9AMAPT | |
| SCHEMBL21533538 | 0.74 | TLR7 (0.39) | MEN1KMT2ASMN1; SMN2TP53RAB9A | |
| SCHEMBL21533487 | 0.73 | HCRTR1 (0.46) | MEN1KMT2ASMN1; SMN2TP53RAB9A | |
| SCHEMBL21533488 | 0.70 | APEX1 (0.48) | MEN1KMT2ASMN1; SMN2RAB9AHPGD | |
| SCHEMBL3864788 | 0.70 | TLR7 (0.70) | — | |
| SCHEMBL7689381 | 0.69 | SMN1; SMN2 (0.70) | MEN1KMT2ASMN1; SMN2TP53RAB9A | |
| SCHEMBL5349651 | 0.67 | TLR7 (0.75) | — | |
| SCHEMBL22777773 | 0.66 | TBXA2R (0.43) | MEN1KMT2ARAB9ANPC1HPGD | |
| SCHEMBL21533485 | 0.66 | HDAC1 (0.42) | MEN1KMT2ASMN1; SMN2TP53RAB9A | |
| SCHEMBL6307635 | 0.66 | EGFR (0.57) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330167-A1 | ACTIVATORS OF HIV LATENCY | NFATC1, EP300, CD69 | MEN1 4858/4885KMT2A 535/4885SMN1; SMN2 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.